Publication

A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.

Pratt, G
; 
Yap, C
; 
Oldreive, C
; 
Slade, D
; 
Bishop, R
; 
Griffiths, M
; 
Dyer, M
; 
Fegan, C
; 
Oscier, D
; 
Pettitt, A
... show 9 more
Citations
Altmetric:
Abstract
Authors
Pratt, G
Yap, C
Oldreive, C
Slade, D
Bishop, R
Griffiths, M
Dyer, M
Fegan, C
Oscier, D
Pettitt, A
Matutes, E
Devereux, S
Allsup, D
Bloor, Adrian
Hillmen, P
Follows, G
Rule, S
Moss, P
Stankovic, T
Affiliation
University Hospitals Birmingham NHS Foundation Trust, Birmingham
Description
Date
2017-06-23
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Article
Citation
A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. 2017 Br J Haematol
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/620438
Embedded videos